corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 11574

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

Japsen B.
Firms to study why some vulnerable to drug reactions
Chicago Tribune 2007 Sep 27
http://www.chicagotribune.com/business/chi-thu_notebook_0927sep27,0,6328446.story


Full text:

A better understanding of why some people are predisposed to dangerous drug interactions and serious illness when taking new prescriptions will be the charge of a non-profit group being formed by several of the world’s largest pharmaceutical companies and the federal government.

Called the International Serious Adverse Event Consortium, the group will be announced Thursday by the Food and Drug Administration and seven drugmaking founders of the organization that include North Chicago-based Abbott Laboratories, Johnson & Johnson and Pfizer Inc. The new group’s office will be based in north suburban Deerfield.

Drug companies and the FDA alike have been under fire for perceived lax monitoring of prescription drugs once they reach the market. This was heightened three years ago this Sunday when Merck & Co. pulled Vioxx from the market after a study showed the drug, which had been on the market for more than four years, was associated with an increased risk of heart attacks and strokes.

Drug companies, which have large databases of reports from patients and doctors on how their drugs interact with patients, say they will use their information to conduct studies that will provide a map of “genetic markers” linked to serious adverse events, or SAEs, which can lead to serious injuries or death. Databases from universities and other consortia will also be used.

But because new medications such as expensive genetically-engineered drugs are complicated and costly to develop, these companies and their academic partners in the consortium cannot tackle the issue on their own.

“Patient safety is one of the biggest priorities of the FDA, and we are encouraged by this new consortium that will accelerate and advance our understanding of genetic variants associated with serious drug-related adverse events,” said Dr. Janet Woodcock, the FDA’s deputy commissioner and chief medical officer. “Given the considerable size and cost of conducting safety studies, a coordinated strategic partnership between industry, academia and government can more rapidly advance this critical science.”

The group hopes to reduce an estimated 150,000 deaths and annual costs of more than $100 billion to the U.S. economy from serious adverse events by addressing more safety issues for drugs before they reach the market.

Its first two studies will look at drug-related liver toxicity and Stevens-Johnson syndrome, a severe skin problem that leads to blisters, among other health problems.

“The traditional research model only provides one piece of the puzzle in understanding the genetic variations that could lead to an increased risk of an adverse event,” said the consortium’s chairman and chief executive, Arthur Holden, formerly an executive at diagnostic-test maker Illumina Inc. “The most efficient way to study drug-induced SAEs is to create a global, publicly available ‘knowledge base’ that will help identify the genetic variations that may predict SAEs.”

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








Far too large a section of the treatment of disease is to-day controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudo-science...
The blind faith which some men have in medicines illustrates too often the greatest of all human capacities - the capacity for self deception...
Some one will say, Is this all your science has to tell us? Is this the outcome of decades of good clinical work, of patient study of the disease, of anxious trial in such good faith of so many drugs? Give us back the childlike trust of the fathers in antimony and in the lancet rather than this cold nihilism. Not at all! Let us accept the truth, however unpleasant it may be, and with the death rate staring us in the face, let us not be deceived with vain fancies...
we need a stern, iconoclastic spirit which leads, not to nihilism, but to an active skepticism - not the passive skepticism, born of despair, but the active skepticism born of a knowledge that recognizes its limitations and knows full well that only in this attitude of mind can true progress be made.
- William Osler 1909